To have your comment included in a future podcast, call 617-440-4374. Please leave your name, number, and the podcast ID number.
Archive for July, 2009
Podcast 51: In pregnant women with suspected H1N1, treat promptly! A conversation with Denise Jamieson of the CDC.
Joe Elia • July 31st, 2009
It’s simple: pregnant women (for un-simple reasons) are at greater risk for flu complications. It’s true even among hitherto apparently healthy patients. We’ve got a conversation with a CDC researcher who’s just published a paper in Lancet that urges prompt treatment, even in the face of pending lab results, with antivirals. Contact us at 1-617-440-4374. [...]
Podcast 50: A re-podcast of an interview from February regarding the FDA’s plans for tightening regulations on opioid use.
Joe Elia • July 19th, 2009
Categories: opioid drugs, pain, Uncategorized
This week the FDA approved a form of fentanyl that can be administered through the buccal mucosa — but its label carries boxed warnings. And two weeks ago, the opioid propoxyphene got boxed warnings on its Darvon and Darvocet formulations. The FDA is trying to regulate the opioids more closely, reminding prescribers and users of [...]
Podcast 49: Three RASS Study researchers discuss their findings on the lack of benefit of renin-angiotensin blockade in the primary prevention of diabetic nephropathy in Type 1 diabetes.
Joe Elia • July 10th, 2009
Categories: diabetes type 1, nephropathy, renin-angiotensin blockade
We talk with Drs. Michael Mauer, Ronald Klein, and Bernard Zinman about their paper in the July 2 New England Journal of Medicine reporting on the RASS study (Renin-Angiotensin System Study). They found that blockade of the renin-angiotensin system was not effective in the primary prevention of diabetic nephropathy in Type 1 diabetes. This week’s [...]
Joe Elia • July 2nd, 2009
Categories: bone density, Osteoporosis
Scanning patients on bisphosphonates within the first 3 years of therapy is just wasted effort, and may even be misleading clinically. That’s what researchers conclude after reanalysis of FIT trial data on some 6500 women taking either alendronate or placebo. Prof. Les Irwig of the University of Sydney talks about his team’s findings and what [...]